Legal Challenge To First Japan Rituxan Biosimilar Dismissed

 
• By Ian Haydock

First Japan legal ruling means biosimilar competition can continue to gnaw away at Rituxan, at least for now, as Chugai faces rising challenges to its mature oncology portfolio.

Destruction of leukaemia cell, conceptual image. 3D illustration which can be used to illustrate blood cancer treatment
Rituxan Faces Continuing Biosimilar Competition In Japan • Source: Shutterstock

More from Japan

More from Focus On Asia